The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
Open accessAbstract
Background —The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with coronary heart disease (CHD) and serum cholesterol 5.5 to 8.0 mmol/L (213 to 310 mg/dL) with triglycerides ≤2.5 mmol/L (220 mg/dL) to simvastatin 20 to 40 mg or placebo once daily. Over the median follow-up period of 5.4 years, one or more major coronary events (MCEs) occurred in 622 (28%) of the 2223 patients in the placebo group and 431 (19%) of the 2221 patients in the simvastatin group (34% risk reduction, P <.00001). Simvastatin produced substantial changes in several lipoprotein components, which we have attempted to relate to the beneficial effects observed. Methods and Results —The Cox proportional hazards model was used to assess the relationship between lipid values (baseline, year 1, and percent change from baseline at year 1) and MCEs. The reduction in MCEs within the simvastatin group was highly correlated with on-treatment levels and changes from baseline in total and LDL cholesterol, apolipoprotein B, and less so with HDL cholesterol, but there was no clear relationship with triglycerides. We estimate that each additional 1% reduction in LDL cholesterol reduces MCE risk by 1.7% (95% CI, 1.0% to 2.4%; P <.00001). Conclusions —These analyses suggest that the beneficial effect of simvastatin in individual patients in 4S was determined mainly by the magnitude of the change in LDL cholesterol, and they are consistent with current guidelines that emphasize aggressive reduction of this lipid in CHD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Law, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
Prevention of coronary heart disease in clinical practice
PYÖRÄLÄ, K., BACKER, G. D., GRAHAM, I., POOLE-WILSON, P., & WOOD, D. (1994) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a060388 · Cited by 1,163
Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077
Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study
Manninen, V. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410050061031 · Cited by 957
Verschuren, W. M. M. (1995) · JAMA · doi:10.1001/jama.1995.03530020049031 · Cited by 573
Lipids and risk of coronary heart disease The Framingham Study
Castelli, W. P., Anderson, K., Wilson, P. W. F., & Levy, D. (1992) · Annals of Epidemiology · doi:10.1016/1047-2797(92)90033-m · Cited by 547
Chen, Z., Peto, R., Collins, R., MacMahon, S., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537
Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials
Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., & Furberg, C. D. (1998) · Circulation · doi:10.1161/01.cir.97.10.946 · Cited by 442
Pedersen, T. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.18.2085 · Cited by 286
Self-citationBaseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
Scandinavian Simvastation Survival Study Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)90926-5 · Cited by 255
Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease
Rapaport, E. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500040071040 · Cited by 224
Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin survival study (4S)
Kjekshus, J., & Pedersen, T. R. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80473-1 · Cited by 173
Self-citationThe Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day
Davidson, M. H., Stein, E. A., Dujovne, C. A., Hunninghake, D. B., Weiss, S. R., Knopp, R. H., Illingworth, D. R., Mitchel, Y. B., Melino, M. R., Zupkis, R. V., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00742-4 · Cited by 167
Self-citationWhen to Start Cholesterol-Lowering Therapy in Patients With Coronary Heart Disease
Grundy, S. M., Balady, G. J., Criqui, M. H., Fletcher, G. F., Greenland, P., Hiratzka, L. F., Miller, N. H., Kris‐Etherton, P. M., Krumholz, H. M., LaRosa, J. C., et al. (1997) · Circulation · doi:10.1161/01.cir.95.6.1683 · Cited by 141
Burchfiel, C. M., Laws, A., Benfante, R., Goldberg, R. J., Hwang, L., Chiu, D., Rodríguez, B. L., Curb, J. D., & Sharp, D. S. (1995) · Circulation · doi:10.1161/01.cir.92.6.1430 · Cited by 78
Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort
Szatrowski, T. P., Peterson, A. V., Shimizu, Y., Prentice, R. L., Mason, M. W., Fukunaga, Y., & Kato, H. (1984) · Journal of Chronic Diseases · doi:10.1016/0021-9681(84)90007-9 · Cited by 62
Logical and statistical fallacies in the use of cox regression models
Wolfe, R. A., & Strawderman, R. L. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90039-6 · Cited by 55
Cited by
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
“001 Diabetes Yes No 116/318 (36) 214/949 (23) 88/309 (28) 170/955 (18) 24 (¡0.”
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationWood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Metadata
- Authors
- Pedersen, T. R., Olsson, A. G., Færgeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T., Thorgeirsson, G., Pyörälä, K., Miettinen, T., Christophersen, B., Tobert, J. A., Musliner, T. A., & Cook, T. J.
- Venue
- Circulation
- Published
- 1998-04-21
- Volume
- 97
- Issue
- 15
- Pages
- 1453-1460
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2011277263
- Cited by
- 621
- References
- 27
- FWCI
- 67.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.